Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the environmental liabilities hidden in Ingevity’s 200-page 10-K or tracking resin cost swings across three segments can feel overwhelming. Ingevity’s specialty chemical operations—Performance Chemicals, Advanced Polymer Technologies, and activated-carbon-driven Performance Materials—create dense disclosures that analysts must sift through line by line.
Our platform turns that burden into clarity. Stock Titan delivers AI-powered summaries for every document, from the Ingevity annual report 10-K simplified to an Ingevity quarterly earnings report 10-Q filing. Need the latest Ingevity 8-K material events explained after a caprolactone plant outage? Want Ingevity Form 4 insider transactions real-time alerts before the market opens? We stream filings directly from EDGAR, tag key metrics such as segment EBITDA or remediation accruals, and answer natural questions like “understanding Ingevity SEC documents with AI.”
Here’s how professionals use the page:
- Monitor Ingevity insider trading Form 4 transactions and gauge executive confidence.
- Compare asphalt-additive margin trends with our Ingevity earnings report filing analysis.
- Review the Ingevity proxy statement executive compensation to align pay with performance.
Every filing—10-K, 10-Q, 8-K, DEF 14A, S-8, and more—is parsed, highlighted, and cross-linked. Whether you’re screening Ingevity executive stock transactions Form 4 or simply want Ingevity SEC filings explained simply, our real-time updates and expert context keep you ahead of the curve.
ChoiceOne Financial Services, Inc. (COFS) filed a Form 4 reporting that director Eric E. Burrough acquired 579 shares of common stock on July 1, 2025. The transaction is coded “A,” indicating a grant or other non-open-market acquisition, at a stated price of $28.70 per share. Following the transaction, Burrough’s direct ownership increased to 169,259 shares. No derivative security activity or additional insiders were disclosed.
The purchase is relatively small compared with the director’s existing stake and does not materially alter the company’s share count, capital structure, or governance profile.
Ingevity Corporation (NGVT) Form 4 filing: Director Francis David Segal reported the acquisition of 507 common shares on 07/01/2025 at an implied price of $44.40 per share. The shares were received through the vesting of deferred stock units (DSUs) elected in lieu of quarterly director fees under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following the transaction, Segal’s direct beneficial ownership increased to 5,241 shares. No derivative securities were involved, and the transaction was coded “A” (acquisition) rather than an open-market purchase or sale. Because DSUs settle only after board service ends, the filing signals continued equity alignment but does not represent immediate cash investment.
Ingevity Corporation (NYSE: NGVT) filed a Form 8-K dated 1 July 2025 announcing the departure of S. Edward Woodcock, Executive Vice President and President of the Performance Materials segment (Item 5.02). The separation is effective the same day and a search for his successor has begun.
The company and Mr. Woodcock executed a Letter Agreement that mirrors provisions in his 2017 Severance and Change of Control Agreement. Key cash benefits include:
- A lump-sum payment within 30 days for accrued salary, prorated 2025 annual incentive, and unused vacation.
- Severance equal to one year of current base salary plus 2025 target bonus, payable monthly over 12 months.
- An additional $500,000 lump-sum tied to an October 2024 incentive award.
All consideration is conditioned on customary release of claims and ongoing covenant compliance (confidentiality, non-disparagement, non-competition, non-solicitation). The full Letter Agreement will be filed with the company’s Q2-25 10-Q.
Under Item 7.01, Ingevity furnished (but did not file) a press release (Exhibit 99.1) announcing the leadership change. No financial statements or earnings data were included.
FAQ
What is the current stock price of Ingevity (NGVT)?
What is the market cap of Ingevity (NGVT)?
What are the core business segments of Ingevity Corp?
How does Ingevity generate its revenue?
Which industries benefit from Ingevity's products?
How does Ingevity maintain quality and innovation?
What sets Ingevity apart from other chemical manufacturers?
How does Ingevity support its customer base?
Which regions are primarily served by Ingevity Corp?
How does Ingevity address competitive pressures in its industry?
